Immunovant, Inc. IMVT
We take great care to ensure that the data presented and summarized in this overview for Immunovant, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IMVT
View all-
Vanguard Group Inc Valley Forge, PA6.48MShares$164 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.48MShares$114 Million0.0% of portfolio
-
State Street Corp Boston, MA3.64MShares$92.5 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.96MShares$75.2 Million2.01% of portfolio
-
Armistice Capital, LLC New York, NY2.16MShares$54.9 Million0.95% of portfolio
-
Alpine Global Management, LLC New York, NY1.88MShares$47.8 Million15.89% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.86MShares$47.3 Million0.01% of portfolio
-
Viking Global Investors LP1.81MShares$45.9 Million0.22% of portfolio
-
Logos Global Management LP San Francisco, CA1.78MShares$45.1 Million5.34% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.38MShares$35.1 Million0.11% of portfolio
Latest Institutional Activity in IMVT
Top Purchases
Top Sells
About IMVT
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Insider Transactions at IMVT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 22
2024
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
3,247
-0.72%
|
$94,163
$29.65 P/Share
|
|
May 22
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,163
-1.54%
|
$468,727
$29.65 P/Share
|
|
May 22
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,042
-1.12%
|
$117,218
$29.65 P/Share
|
|
May 22
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,242
-0.94%
|
$94,018
$29.65 P/Share
|
|
May 22
2024
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,247
-0.86%
|
$94,163
$29.65 P/Share
|
|
Apr 24
2024
|
Jay S Stout Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
7,239
-4.67%
|
$202,692
$28.9 P/Share
|
|
Apr 24
2024
|
Michael Geffner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,261
-2.25%
|
$91,308
$28.9 P/Share
|
|
Apr 24
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,963
-1.14%
|
$110,964
$28.9 P/Share
|
|
Apr 17
2024
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,280
-0.54%
|
$240,120
$29.37 P/Share
|
|
Apr 17
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
9,827
-1.38%
|
$284,983
$29.37 P/Share
|
|
Apr 17
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,253
-1.66%
|
$355,337
$29.37 P/Share
|
|
Apr 17
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
34,079
-1.58%
|
$988,291
$29.37 P/Share
|
|
Apr 17
2024
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,115
-1.1%
|
$293,335
$29.37 P/Share
|
|
Apr 09
2024
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,053
-0.23%
|
$32,643
$31.18 P/Share
|
|
Apr 09
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,689
-0.98%
|
$114,359
$31.18 P/Share
|
|
Apr 09
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,807
-0.44%
|
$149,017
$31.18 P/Share
|
|
Apr 02
2024
|
Douglas J. Hughes Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,255
+8.26%
|
-
|
|
Apr 02
2024
|
Andrew J. Fromkin Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,255
+10.12%
|
-
|
|
Apr 02
2024
|
Atul Pande Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,255
+10.65%
|
-
|
|
Apr 02
2024
|
George V Migausky Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,255
+8.51%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 5.13M shares |
|---|---|
| Open market or private purchase | 1.53M shares |
| Open market or private sale | 581K shares |
|---|